The AVENIO Tumor Tissue CGP Kit V2 is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue-derived DNA samples. With a 335-gene panel aligned with the FoundationOne®CDx panel design and bioinformatics using the FoundationOne®Analysis Platform, the kit leverages the proven technology of Foundation Medicine and expertise of Roche to help your lab obtain reliable genomic insights.1,2
AVENIO Tumor Tissue CGP Kit V2
For Research Use Only. Not for use in diagnostic procedures.
Accelerate answers to empower life-changing decisions
Leverage the power of Roche and Foundation Medicine®
Experts in personalized medicine and comprehensive genomic profiling: 800+ peer reviewed publications, 1.2 million+ clinical samples reported.1,3
Unlock high-quality meaningful genomic insights
Analyzes 335 relevant genes, four classes of genomic alterations, and complex genomic signatures including TMB, MSI, gLOH and the newly added HRDsig.1,2,4
Utilize fast and convenient NGS workflows
One workflow from DNA extraction to data analysis. Fast 2-day library prep and short 1-hour ligation with a total 5-day turnaround time from DNA extraction to result generation.1,2
FoundationOne® Analysis Platform + AVENIO Connect Software
The FoundationOne® Analysis Platform processes the AVENIO Tumor Tissue CGP Kit V2 sequencing data from the Illumina NextSeq500/500/550Dx (Research Use Only mode) instruments,* and produces files with filtered variant calls and QC metrics which are made available to the user through AVENIO Connect Software. Leveraging the Foundation Medicine knowledgebase with 1.3 million+ genomic profiles,4 this post-sequencing analysis software makes it easy for customers to analyze samples and access the information they need.2,3
Robust analytical variant detection performance across genomic alterations and signatures
Sequencing libraries were prepared from 316 FFPE tissue-derived DNA samples on the Illumina NextSeq 550 high-throughput sequencing flowcell using the AVENIO Tumor Tissue CGP Kit V2.1
Classification |
Detected Variants/Signatures |
Short Variants |
99.7% |
Rearrangements |
89.9% |
CNA |
99.8% |
MSI high |
100% |
TMB high |
100% |
gLOH high |
100% |
HRDsig positive |
91.7% |
Results are from 60 million reads per sample on Illumina NextSeq 550 (~12 samples per flowcell) to determine performance by comparing to the reference method (FoundationOne® CDx).2 For this analysis, high or positive signatures were defined as follows: MSI-High ≥ 0.0124, TMB-High ≥ 10.0 mutations/Mb, gLOH-Positive ≥ 0.16, and HRDsig-Positive ≥ 0.7. Samples with scores in the marginal ranges, MSI (0.0041-0.0124; “equivocal” status), TMB (8.0-12.0 mutations/Mb), and gLOH (0.14-0.18), were excluded.The AVENIO Tumor Tissue CGP Kit V2 is a Research Use Only assay and should not be used for diagnostic procedures. Users must determine the complex signature cut-offs based on their research needs.
High performance as demonstrated by key sequencing metrics
Sequencing libraries were prepared from 316 FFPE tissue-derived DNA samples on the Illumina NextSeq 550 high-throughput sequencing flowcell using the AVENIO Tumor Tissue CGP Kit V2. The graphs show sequencing QC metrics obtained through the FoundationOne® Analysis Platform.1
Results are from 60 million reads per sample on Illumina NextSeq 550 (~12 samples per flowcell).1
Strong agreement in allele frequencies and signature scores to the reference method
Sequencing libraries were prepared from 316 FFPE tissue-derived DNA samples on the Illumina NextSeq 550 high-throughput sequencing flowcell using the AVENIO Tumor Tissue CGP Kit V2. Results were compared with the analytical performance with the reference method and are shown.1
Results are from 60 million reads per sample on Illumina NextSeq 550 (~12 samples per flowcell) to determine performance by comparing to the reference method.1 For this analysis, high or positive signatures were defined as follows: MSI-High ≥ 0.0124, TMB-High ≥ 10.0 mutations/Mb, gLOH-Positive ≥ 0.16, and HRDsig-Positive ≥ 0.7. Samples with scores in the marginal ranges, MSI (0.0041-0.0124; “equivocal” status), TMB (8.0-12.0 mutations/Mb), and gLOH (0.14-0.18), were excluded. The AVENIO Tumor Tissue CGP Kit V2 is a Research Use Only assay and should not be used for diagnostic procedures. Users must determine the complex signature cut-offs based on their research needs.
